Literature DB >> 3697655

Increased activities of thymidine kinase isozymes in human mammary tumours.

S Sakamoto, T Iwama, M Ebuchi, K Tsukada, T Sagara, T Kawasaki, S Murakami, N Kasahara, H Kudo, R Okamoto.   

Abstract

Thymidine kinase, the enzyme in the pyrimidine salvage pathway, and its isozymes were examined in 10 specimens of normal mammary gland, 10 fibroadenomas and 11 adenocarcinomas in human breasts. The average thymidine kinase activities in fibroadenomas and adenocarcinomas were about 3 and 8 times that in normal mammary gland. The mammary thymidine kinase isozymes were separated into two types by diethylaminoethyl (DEAE) cellulose column chromatography. The activity of the thymidine kinase isozyme eluted with 0.1 M sodium chloride in buffer was twofold higher in fibroadenomas and fourfold higher in adenocarcinomas than that in normal tissue. In adenocarcinomas, but not fibroadenomas, the activity of the other isozyme eluted with buffer alone was increased to 22-fold that in normal tissues. As the activity of the latter isozyme was not affected by deoxycytidine triphosphate, it may be involved closely in DNA replication.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3697655     DOI: 10.1002/bjs.1800730409

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  3 in total

1.  Potential impact of [18F]3'-deoxy-3'-fluorothymidine versus [18F]fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer.

Authors:  D L Francis; D Visvikis; D C Costa; T H A Arulampalam; C Townsend; S K Luthra; I Taylor; P J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-09       Impact factor: 9.236

2.  Thymidine kinase in breast cancer.

Authors:  J F Robertson; K L O'Neill; M W Thomas; P G McKenna; R W Blamey
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

3.  Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients.

Authors:  P G McKenna; K L O'Neill; W P Abram; B M Hannigan
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.